RVL Pharmaceuticals plc: insider trades · United States · SEC (Form 4)

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc is a specialty pharmaceutical company that was listed on the U.S. NASDAQ market and operated from the United States, with principal business activities centered in Bridgewater, New Jersey. The company’s commercial identity was built around underserved therapeutic niches in ocular medicine and medical aesthetics, and its best-known asset was UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution) 0.1%, a prescription treatment for acquired blepharoptosis, or droopy eyelid, in adults. RVL’s model combined product commercialization with tech-enabled access and integrated fulfillment designed to support both clinicians and patients. ([rvlpharma.com](https://www.rvlpharma.com/about-us?utm_source=openai)) From a historical standpoint, RVL Pharmaceuticals plc was organized as an Irish public limited company while its operating footprint was primarily U.S.-based. SEC filings identified Bridgewater, New Jersey, as the company’s principal executive office, and earlier filings also referenced a New Jersey pharmacy operation in Sayreville that supported the Upneeq supply and distribution chain. This structure is important for investors because it highlights a company incorporated outside the United States but commercially anchored in the U.S. market. ([ir.rvlpharma.com](https://ir.rvlpharma.com/company-profile?utm_source=openai)) RVL’s core business was that of a focused specialty pharma company rather than a broad diversified pharmaceutical platform. Its strategy relied on a narrow portfolio built around a flagship brand, with Upneeq serving as the main value driver. The company targeted physicians and aesthetic practices that treat eyelid ptosis and related cosmetic or functional concerns, aiming to differentiate itself through a category-creating product, specialized commercial execution, and patient-access tools. In competitive terms, RVL operated in a niche where clinical differentiation, regulatory positioning, and sales-force execution mattered more than scale. ([rvlpharma.com](https://www.rvlpharma.com/about-us?utm_source=openai)) The most material recent development was financial distress and restructuring. In 2023, RVL’s U.S. operating subsidiaries entered Chapter 11 proceedings, and SEC disclosures stated that the former public parent RVL Pharmaceuticals plc was expected to be wound down, with public equity cancellation anticipated and no recovery for ordinary shareholders. For market participants, that is a critical point: even if the company name still appears in historical market data or corporate references, the equity story was effectively transformed by the restructuring process. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1739426/000110465923121234/tm2331439d1_8k.htm?utm_source=openai)) In summary, RVL Pharmaceuticals plc should be viewed as a U.S.-operating, NASDAQ-listed specialty pharma company built around Upneeq, with a concentrated product profile, a Bridgewater, New Jersey headquarters, and a recent corporate history dominated by restructuring rather than growth. For French-speaking investors, the key takeaway is that the company’s commercial narrative is straightforward, but its capital structure and public-shareholder outcome were materially affected by the 2023 reorganization and wind-down process. ([ir.rvlpharma.com](https://ir.rvlpharma.com/news-releases/rvl-pharmaceuticals-plc-announces-prepackaged-reoganization-of-certain-us-subsidiaries?utm_source=openai))